| 郑 媞,董欣敏,刘 洋,贾馨宇,王 磊.靶向治疗联合介入治疗对晚期非小细胞肺癌疗效及远期复发率的影响[J].现代生物医学进展英文版,2023,(13):2483-2488. |
| 靶向治疗联合介入治疗对晚期非小细胞肺癌疗效及远期复发率的影响 |
| Effect of Targeted Therapy Combined with Interventional Therapy on the Efficacy and Long-term Recurrence Rate of Advanced Non-small Cell Lung Cancer |
| Received:February 10, 2023 Revised:February 28, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.13.016 |
| 中文关键词: 靶向治疗 介入治疗 晚期非小细胞肺癌 复发率 |
| 英文关键词: Targeted therapy Interventional treatment Advanced non-small cell lung cancer Recurrence rate |
| 基金项目:内蒙古自治区自然科学基金项目（2020LH08041） |
|
| Hits: 531 |
| Download times: 414 |
| 中文摘要: |
| 摘要 目的：探讨靶向治疗联合介入治疗对晚期非小细胞肺癌疗效及远期复发率的影响。方法：选取我院2017年1月到2019年12月收治的220例晚期非小细胞肺癌患者作为研究对象进行回顾性分析，依照患者选择的不同治疗方式进行分组，将选择单纯PP方案化疗的110例患者分为对照组，将选择在PP方案化疗基础上增加靶向治疗联合125I放射性粒子植入介入治疗的110例患者分为观察组，对比两组患者生存情况，治疗前与治疗3个月后血管生成因子与肿瘤标志物水平，1年、2年、3年复发率情况以及不良反应情况。结果：观察组中位PFS为11.26（2.38~24.13），对照组中位PFS为9.25（2.24~17.22），观察组高于对照组，差异具有统计学意义（x2=4.536，P=0.041）。观察组中位OS为21.23（4.84~62.73），对照组中位OS为16.52（5.27~50.27），观察组高于对照组（x2=5.262，P=0.022）；两组患者治疗前碱性成纤维细胞生长因子（bFGF）、血管内皮生长因子（VEGF）血管生成因子，人细胞角蛋白21-1片段（Cyfra21-1）、糖类抗原125（CA125）肿瘤标志物水平对比无明显差异（P＞0.05），治疗后两组患者bFGF、VEGF血管生成因子，CA125、Cyfra21-1肿瘤标志物水平均降低，且观察组低于对照组（P＜0.05）；观察组患者治疗后远期总复发率明显低于对照组（P＜0.05）；两组患者0~Ⅱ和Ⅲ~Ⅳ不良反应情况对比无明显差异（P＞0.05）。结论：对晚期非小细胞肺癌患者在常规化疗基础上增加靶向治疗联合125I放射性粒子植入介入治疗能够提升患者生存期和无进展生存期，同时能够改善患者机体炎症标志物水平，降低远期复发率，安全性较高，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of targeted therapy combined with interventional therapy on the efficacy and long-term recurrence rate of advanced non-small cell lung cancer. Methods: 220 patients with advanced non-small cell lung cancer admitted to our hospital from January 2017 to December 2019 were selected as the study subjects for retrospective analysis. According to the different treatment methods selected by the patients, 110 patients who chose simple PP regimen chemotherapy were divided into matched group, and 110 patients who chose targeted therapy combined with 125I radioactive particle implantation on the basis of PP regimen chemotherapy were divided into observation group, The survival of the two groups, the levels of angiogenic factors and tumor markers before and after treatment for 3 months, the 1-year, 2-year and 3-year recurrence rates and adverse reactions were compared. Results: The median PFS of the observation group was 11.26 (2.38-24.13), and the median PFS of the matched group was 9.25 (2.24-17.22). The observation group was higher than the matched group(x2=4.536, P=0.041), as shown in Figure 1A. The median OS of the observation group was 21.23 (4.84~62.73), and the median OS of the matched group was 16.52 (5.27~50.27). The observation group was higher than the matched group, and the difference was statistically significant（x2=5.262, P=0.022）; There was no difference in the levels of basic fibroblast growth factor(bFGF), vascular endothelial growth factor (VEGF), angiogenesis factor, human cytokeratin 21-1 fragment (Cyfra21-1) and carbohydrate antigen 125(CA125) tumor markers between the two groups before treatment (P>0.05), After treatment, the levels of bFGF, VEGF angiogenesis factor, CA125 and Cyfra21-1 tumor markers in the two groups were lower than those in the matched group(P<0.05); The long-term total recurrence rate of patients in the observation group was lower than that in the matched group (P<0.05); There was no difference in the adverse reactions of 0~II and III~IV between the two groups(P>0.05). Conclusion: Targeted therapy combined with 125I radioactive particle implantation can improve the survival and progression-free survival of patients with advanced non-small cell lung cancer on the basis of conventional chemotherapy, improve the level of inflammatory markers in patients, reduce the long-term recurrence rate, and have high safety, which is worthy of clinical promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
